速递|预计礼来替尔泊肽的全球销售额将达620亿美金,成为2030年全球药王

GLP1减重宝典
Jul 14, 2025

整理 | GLP1减重宝典内容团队根据Evaluate Pharma的数据,受益于糖尿病和肥胖治疗药物销售的持续增长,礼来(Eli Lilly)有望在2030年成为全球处方药销售额最高的生物制药公司,预计届时销售收入将达到1130亿美元,远超排名第二的诺和诺德(Novo Nordisk),后者预计为840亿美元。在其发布的《2025年全球前瞻》报告中,Evaluate指出,糖尿病与肥胖药物将继续...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10